Bourbon Street Finale: Much Ado About Something For Newer Diabetes Drugs
Executive Summary
Fresh data on type 2 diabetes drugs from two landmark outcomes studies are complex and somewhat baffling. But there is one simple take-home message for industry: classes of drug that should not be prone to causing hypoglycemia - think GLP-1s and DPP-4s - stand to benefit from the results